Compensated Awareness Post View
Disclaimer
Stellar Biotechnologies, Inc. (SBOTF) Announces Jump in Sales and Service with Q1 2015 Results
Stellar Biotechnologies, California-based world leader in the sustainable manufacture of the important KLH immune-stimulating molecule for a variety of immunotherapy and diagnostic applications, today announced financial results for Q1 2015, the quarter ended December 31, 2014, showing a healthy increase in revenue, including both product sales and service contracts.
Stellar produces the immune-stimulating protein Keyhole Limpet Hemocyanin (KLH) used, among other things, for immunotherapies that target cancer, immune disorders, Alzheimer’s and inflammatory diseases. The company uses proprietary methods, facilities, and technologies.
First Quarter Ended December 31, 2014 Results:
• Revenues for the period were $212,661, compared to revenue for the three months ended December 31, 2013 of $58,825. Q1 2015 revenue included product sales of $152,661, compared to $16,085 for the three months ended December 31, 2013. Q1 2015 contract services revenue was $60,000, compared to $15,000 for the prior year.
• Quarterly net loss for Stellar dropped dramatically from $5,577,190 for the period ending December 31, 2013 to $1,343,477 for Q1 2015.
• R&D expenses went down from $548,225 for the period ending December 31, 2013 to $418,821 for Q1 2015.
• Other operating expenses went down from $1,206,207 for the period ending December 31, 2013 to $1,119,254 for Q1 2015.
In 2014, Stellar changed its fiscal year end from August 31 to September 31 to synchronize it with calendar quarters. To view the company’s filings under Form 20-F, Form 10-K, 10-Q and 8-K, visit the U.S. SEC website (www.sec.gov). To view the company’s filings with the Canadian Securities Administrators (“CSA”), including the Management Discussion and Analysis and related consolidated financial statements, visit the CSA’s SEDAR website (www.sedar.com).
For more information on Stellar Biotechnologies, visit www.StellarBiotechnologies.com
